drugset / Trial / NCT01067690

Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma

NCT01067690

Phase 2 Completed 25 enrolled Barbara Ensoli, MD, PhD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the clinical response to daily Indinavir oral administration in association with a conventional chemotherapy based on cycles of systemic Vinblastine +/- Bleomycin in patients affected by advanced classical (non HIV-associated) Kaposi's sarcoma

Timeline

Start
2008-06
Primary completion
2015-10
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 15 mg Intramuscular
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg Oral
Subject Vinblastine Small molecule 10 mg Intravenous

Indications